Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a global life sciences manufacturer with two segments, protein sciences (75% of revenue) and diagnostics and genomics (25% of revenue). The company has a global presence with operations in the US (55% of revenue), Europe, the Middle East, Africa, the UK, and Asia-Pacific. The pending acquisition of Wilson Wolf is seen as a transformative move with potential for improved margins and growth opportunities. Regulatory risk is low and an important driver of future growth is the expected rebound in biotech demand.

Bears say

Bio-Techne is a global life science tools company that has seen a mixed track record in M&A activity, but has made successful acquisitions in the past. However, concerns about potential share loss to larger competitors and fast-growing start-ups, as well as the progress of cell therapy development, could lead to downside risks for the company's stock. There is also a possibility of structural growth pressures if wet lab work is diminished by dry lab work in the future. The current 20x EBITDA multiple for Bio-Techne is a premium to the peer group median of 16x, but reflects the company's ongoing business recovery and improving growth momentum.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.